Crossbow Therapeutics
Biotech · Healthcare
Crossbow Therapeutics Secures $77M Series B for Cancer T-Cell Therapies
March 18, 2026$77M · Series B
Crossbow Therapeutics raised $77 million in Series B funding to complete Phase 1 trials of CBX-250 for myeloid cancers and start CBX-663 trials for solid tumors. The round was co-led by Taiho Ventures and Arkin Bio Capital.
Lead Investors
Taiho VenturesArkin Bio Capital
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.